Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 4, 2011, Pages 487-492

  Giordano, Nicola ^a   Papakostas, P ^a   Pecetti, G ^b   Nuti, R ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Medical and Scientific Direction   (Italy)

Author keywords

Cytokines; Endothelin 1; Microvascular damage; Scleroderma; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGEN TYPE 1; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GAMMA INTERFERON; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AUTOIMMUNITY; BLOOD VESSEL INJURY; CELL PROLIFERATION; HUMAN; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

ACTINS; CYTOKINES; ENDOTHELIN-1; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84856009537     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Korn JH. Pathogenesis of systemic sclerosis; arthritis and allied conditions. Koopman WJ editor 2001; 1643-54.
2. Wigley FM. Raynaud's phenomenon. Rheum Dis Clin North Am 1996; 22:765-81. (Pubitemid 26396050)
3. Belch JJP. Raynaud's phenomenon: its relevance to scleroderma. Ann Rheum Dis 1991; 50:839-45.
4. Le Roy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4:351-68.
5. Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol 2010; 19:393-400.
6. Salojin KV, LeTonquze M, Saraux A. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102:178-85. (Pubitemid 27123000)
7. Herrick AL, Illingworth K, Blann A. von Willebrand factor, thrombomodulin, thromboxane, thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55:122-7. (Pubitemid 26050121)
8. Negi S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 3:462-6.
9. Endemann DH. Endothelial dysfunction. J Am Soc Nephrol 2004; 15:1983-92. (Pubitemid 39031337)
10. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995; 54:361-5.
11. Yamamoto T, Takahashi Y, Kuno S, Geshi Y, Sasamori Y, Mori H. Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells. Immunol Cell Biol 1997; 75:340-4. (Pubitemid 27408038)
12. Mayes MD. Endothelin and endothelin receptor antagonist in systemic rheumatic disease. Arthritis Rheum 2003; 48:1190-9. (Pubitemid 36554517)
13. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1. FASEB J 2001; 15:2230-40. (Pubitemid 32927941)
14. Shetty N, Derk C. Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm Allergy Drug Targets 2011; 10:19-26.
15. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151:831-41. (Pubitemid 27385615)
16. Kurn JH. Digital ulcers in systemic sclerosis. Arthritis Rheumatism 2004; 12:3985-93.
17. Iwata S. Regulations of Endothelin-1 induced interleukin-6 production by Ca2+ influx in human airway smooth muscle cells. Eur J Pharmacol 2009; 605:15-22.
18. Finsnes F. Effect of Endothelin antagonism on the production of cytokines in eosinophilic airway inflammation. AJP-Lung 2001; 280:659-65.
19. Gamze K. Effect of Bosentan on the production of proinflammatory cytokines in a rat model of emphysema. Exp Mol Med 2007; 39:614-20.
20. Jurgens UR. Inflammatory responses after Endothelin B receptor activation in human monocyte: new evidence for beneficial anti-inflammatory potency of Etb receptor antagonism. Pulm Pharmacol Ther 2008; 21:533-9.
21. Han JH. The effect of endothelin-1 on the production of interleukin-6 in cultured human detrusor smooth muscle cells, and the effect of interleukin-6 on the contractile response of bladder smooth muscle strips from rats. BJU Int Vol 2009; 107:707-12.
22. Iwata S. Regulation of endothelin-1-induced interleukin-6 production by Ca2+ influx in human airway smooth muscle cells. Eur J Pharmacol 2009; 605:15-22.
23. Chai SP. Endothelin-1 stimulates interleukin-6 secretion from 3T3-L1 adipocytes. Biochim Biopyis Acta Vol 2009; 1790:213-8.
24. Banerjee I. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 2009; 296:694-704.
25. Diaz J. Critical Role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009; 9:1773-883.
26. Sprague AH. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78:539-52.
27. Yndestad A. Modulation of interleukin signalling and gene expression in cardiac myocytes by Endothelin-1. Int J Biochem Cell Biol 2010; 42:263-72.
28. Bellisai F, Morozzi G, Scaccia F, et al. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis. Int J Immunopathol Pharmacol 2011; 24:261-64.
29. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008; 67:1121-6.
30. Leask A. Signaling in fibrosis: targeting the TGF beta, Endothelin 1 and CCN2 axis in scleroderma. Front Biosci 2009; 1:115-22.
31. Shi-Wen X. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006; 26:5518-27. (Pubitemid 44036217)
32. Leask A. Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis and tissue repair online 2010.
33. Hinz B. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170:1807-16. (Pubitemid 47339255)
34. Xu SW. Endothelin-1 induces expression of matrix associated genes in lung fibroblasts through MEK/ ERK. J Biol Chem 2004; 279:23098-103.
35. st Systemic Sclerosis World Congress. Abstracts.
36. Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopy study. Int J Dermatol 1997; 36:272-5. (Pubitemid 27242619)
37. Lewis J. Bosentan therapy for pulmonary arterial hypertension. New England J Med 2002; 346:896-903.
38. Matucci-Cerinic M. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS 2 randomised double blind, placebo controlled trial. Ann Rheum Dis 2011; 70:32-8.